Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 5.55%
As of Monday, October 05, Braveheart Bio, Inc.’s BRVE share price has dipped by 5.55%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Commentary & Analysis
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Up 6.88%
As of Thursday, October 01, Braveheart Bio, Inc.’s BRVE share price has surged by 6.88%, which has investors questioning if this is right time to sell.Michael Rose
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 6.60%
As of Wednesday, September 30, Braveheart Bio, Inc.’s BRVE share price has dipped by 6.60%, which has investors questioning if this is right time to buy.Michael Rose
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 8.47%
As of Friday, September 25, Braveheart Bio, Inc.’s BRVE share price has dipped by 8.47%, which has investors questioning if this is right time to buy.Michael Rose
Why Braveheart Bio, Inc.’s (BRVE) Stock Is Down 6.68%
As of Monday, September 21, Braveheart Bio, Inc.’s BRVE share price has dipped by 6.68%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,753.7 | $494.5 | 53% |
|
| Shares Out (Mil) | 7.4 | 42.5 | 17% |
|
| Institutional Ownership | 0.5% | 84.1% | 1% |
|
| Float (Mil) | na | 45.1 | na |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 700 | 383 | 63% |
|
| Price Change (52-week) |
na | 60.3% | na |
|
| Growth | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $364 | na |
|
| Net Income (TTM) (Mil) | ($95) | ($11) | 11% |
|
| EPS (TTM) | ($14.684) | ($0.700) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($7) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 12% |
|
| Enterprise Value (Q1) (Mil) | $1,623 | $493 | 46% |
|
| Valuation | BRVE | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.33 | na |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BRVE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | 3.0% | na |
|
| ROA | (149.4%) | (22.2%) | 3% |
|
| ROE | 197.8% | (21.4%) | 98% |
|
| Liabilities to Assets | 7.4% | 33.9% | 4% |
|
| F-Score | 1 | 3 | na |
|
Braveheart Bio, Inc. did not pass any screens on 10/2/2026.
